SCHEMBL6503080

SCHEMBL6503080

CC(C)(N)CN1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CHRM2 P08172 1/20 0.47
CHRM4 P08173 1/20 0.47
CHRM1 P11229 1/20 0.47
CHRM3 P20309 1/20 0.47
HPGD P15428 1/20 0.43
EPHX2 P34913 1/20 0.42
TLR8 Q9NR97 1/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
DTYMK P23919 1/20 0.41
ACKR3 P25106 1/20 0.41
RECQL P46063 1/20 0.41
EPHX1 P07099 1/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1306945 0.86 USP2 (0.53) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL1087319 0.84 USP2 (0.51) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL27791397 0.83 USP2 (0.47) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL27341005 0.83 USP2 (0.50) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL1088665 0.83 USP2 (0.50) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL13645410 0.82 USP2 (0.53) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL8242595 0.82 USP2 (0.61) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL9379952 0.81 USP2 (0.49) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL18294 0.81 USP2 (0.69) USP2SMN1; SMN2HPGDEPHX2ALDH1A1
SCHEMBL698803 0.81 USP2 (0.69) USP2SMN1; SMN2HPGDEPHX2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6867299-B2 Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents HOFFMANN-LA ROCHE INC. (US) 2005-03-15 US disclosed
US-20020052513-A1 Oxamide IMPDH inhibitors HOFFMANN-LA ROCHE INC. 2002-05-02 US disclosed
EP-1127883-A2 Oxamides as IMPDH inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2001-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052513-A1 Oxamide IMPDH inhibitors IMPDH1, IMPDH2, IMPA1 USP2 2679/4885SMN1; SMN2 2545/4885CHRM2 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.